Tsiftsoglou Asterios S, Pappas Ioannis S, Vizirianakis Ioannis S
Laboratory of Pharmacology, Department of Pharmaceutical Sciences, Aristotle University of Thessaloniki, Thessaloniki, GR-54124, Greece.
Pharmacol Ther. 2003 Dec;100(3):257-90. doi: 10.1016/j.pharmthera.2003.09.002.
Despite the remarkable progress achieved in the treatment of leukemias over the last several years, many problems (multidrug resistance [MDR], cellular heterogeneity, heterogeneous molecular abnormalities, karyotypic instability, and lack of selective action of antineoplastic agents) still remain. The recent progress in tumor molecular biology has revealed that leukemias are likely to arise from disruption of differentiation of early hematopoietic progenitors that fail to give birth to cell lineage restricted phenotypes. Evidence supporting such mechanisms has been derived from studying bone marrow leukemiogenesis and analyzing differentiation of leukemic cell lines in culture that serve as models of erythroleukemic (murine erythroleukemia [MEL] and human leukemia [K562] cells) and myeloid (human promyelocytic leukemia [HL-60] cells) cell maturation. This paper reviews the current concepts of differentiation, the chemical/pharmacological inducing agents developed thus far, and the mechanisms involved in initiation of leukemic cell differentiation. Emphasis was given on commitment and the cell lineage transcriptional factors as key regulators of terminal differentiation as well as on membrane-mediated events and signaling pathways involved in hematopoietic cell differentiation. The developmental program of MEL cells was presented in considerable depth. It is quite remarkable that the erythrocytic maturation of these cells is orchestrated into specific subprograms and gene expression patterns, suggesting that leukemic cell differentiation represents a highly coordinated set of events that lead to irreversible growth arrest and expression of cell lineage restricted phenotypes. In MEL and other leukemic cells, differentiation appears to be accompanied by differentiation-dependent apoptosis (DDA), an event that can be exploited chemotherapeutically. The mechanisms by which the chemical inducers promote differentiation of leukemic cells have been discussed.
尽管在过去几年白血病治疗方面取得了显著进展,但许多问题(多药耐药性[MDR]、细胞异质性、分子异常异质性、核型不稳定性以及抗肿瘤药物缺乏选择性作用)仍然存在。肿瘤分子生物学的最新进展表明,白血病可能源于早期造血祖细胞分化的破坏,这些祖细胞无法产生细胞系限制表型。支持这种机制的证据来自对骨髓白血病发生的研究以及对培养中的白血病细胞系分化的分析,这些细胞系可作为红白血病(小鼠红白血病[MEL]和人白血病[K562]细胞)和髓系(人早幼粒细胞白血病[HL-60]细胞)细胞成熟的模型。本文综述了当前的分化概念、迄今为止开发的化学/药理诱导剂以及白血病细胞分化起始所涉及的机制。重点关注了定向分化和细胞系转录因子作为终末分化的关键调节因子,以及造血细胞分化中涉及的膜介导事件和信号通路。对MEL细胞的发育程序进行了相当深入的阐述。非常值得注意的是,这些细胞的红细胞成熟被编排成特定的子程序和基因表达模式,这表明白血病细胞分化代表了一系列高度协调的事件,导致不可逆的生长停滞和细胞系限制表型的表达。在MEL和其他白血病细胞中,分化似乎伴随着分化依赖性凋亡(DDA),这一事件可用于化疗。文中讨论了化学诱导剂促进白血病细胞分化的机制。